Muscleblind-like (MBNL) Protein Family Overexpression Lead to Pro-Synthetic Phenotype Modulation of Arterial Human Vascular Smooth Muscle Cells in Diabetes Mellitus
M. O. Ihsan,D. M. Tan,U. Muniasamy,M. S. Ong,X. Y. Lin,C. N. Lee,R. Dorajoo,V. Sorokin
DOI: https://doi.org/10.1016/j.atherosclerosis.2022.06.821
IF: 5.3
2022-01-01
Atherosclerosis
Abstract:Background and Aims : Diabetes Mellitus (DM) is a metabolic disorder affecting ten percent of the worldwide population. The morbidity of DM patients is strongly correlated to cardiovascular diseases (CVD), including cerebrovascular disease, peripheral vascular conditions, and ischemic heart disease. Previous studies have shown that vascular smooth muscle cells (VSMC) from DM patients are often functionally impaired with increased expressions of inflammatory and pro-fibrotic genes. Given its importance in arteriopathy, we aim to understand better the molecular pathway leading to VSMC phenotype modulation in DM.Methods: Primary VSMC were obtained from patients undergoing coronary artery bypass graft surgery. Cells were cultured and harvested for subsequent RNA-Seq analysis, immunoblotting, and phenotypic characterizations.Results: Based on RNA-Seq analysis, we found that DM VSMC transcript highlights pathways associated with vascular remodeling, such as cell adhesion, cell proliferation, and extracellular matrix reorganization. We also found increased expressions of the Muscleblind-like protein family (MBNL1, MBNL2, and MBNL3) in DM VSMC at both mRNA and protein levels. Using network analysis, we established the importance of the MBNL protein family in VSMC phenotype modulation. Further assessment of VSMC phenotypic characteristics revealed that DM VSMC had a pro-synthetic phenotype, marked by increased cell proliferation, downregulation of contractile VSMC-associated genes (ACTA2, ACTG2, and TAGLN), and upregulation of fibroblast-related genes (LUM, DCN, and S100A4) as opposed to non-DM VSMC.Conclusions: Our study highlights the shift in DM human primary VSMC towards pro-synthetic phenotype. The upregulation of the MBNL protein family is likely involved in the VSMC phenotype modulation and could be a potential therapeutic target for DM-associated arteriopathy. Background and Aims : Diabetes Mellitus (DM) is a metabolic disorder affecting ten percent of the worldwide population. The morbidity of DM patients is strongly correlated to cardiovascular diseases (CVD), including cerebrovascular disease, peripheral vascular conditions, and ischemic heart disease. Previous studies have shown that vascular smooth muscle cells (VSMC) from DM patients are often functionally impaired with increased expressions of inflammatory and pro-fibrotic genes. Given its importance in arteriopathy, we aim to understand better the molecular pathway leading to VSMC phenotype modulation in DM. Methods: Primary VSMC were obtained from patients undergoing coronary artery bypass graft surgery. Cells were cultured and harvested for subsequent RNA-Seq analysis, immunoblotting, and phenotypic characterizations. Results: Based on RNA-Seq analysis, we found that DM VSMC transcript highlights pathways associated with vascular remodeling, such as cell adhesion, cell proliferation, and extracellular matrix reorganization. We also found increased expressions of the Muscleblind-like protein family (MBNL1, MBNL2, and MBNL3) in DM VSMC at both mRNA and protein levels. Using network analysis, we established the importance of the MBNL protein family in VSMC phenotype modulation. Further assessment of VSMC phenotypic characteristics revealed that DM VSMC had a pro-synthetic phenotype, marked by increased cell proliferation, downregulation of contractile VSMC-associated genes (ACTA2, ACTG2, and TAGLN), and upregulation of fibroblast-related genes (LUM, DCN, and S100A4) as opposed to non-DM VSMC. Conclusions: Our study highlights the shift in DM human primary VSMC towards pro-synthetic phenotype. The upregulation of the MBNL protein family is likely involved in the VSMC phenotype modulation and could be a potential therapeutic target for DM-associated arteriopathy.